The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs

被引：41

作者：

Bernstein, David I. ^{[1
]}

Farley, Nicholas ^{[1
]}

Bravo, Fernando J. ^{[1
]}

Earwood, Julie ^{[1
]}

McNeal, Monica ^{[1
]}

Fairman, Jeff ^{[2
]}

Cardin, Rhonda ^{[1
]}

机构：

[1] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA

[2] Juvaris BioTherapeut Inc, Burlingame, CA USA

来源：

VACCINE | 2010年 / 28卷 / 21期

关键词：

HSV vaccine; Adjuvant; Genital herpes; Guinea pig; CLDC; RECURRENT GENITAL HERPES; VIRUS TYPE-2; DNA COMPLEXES; IMMUNOTHERAPY; TRANSMISSION; IMMUNIZATION; PREVENTION; INFECTION; DELIVERY; TRIAL;

D O I：

10.1016/j.vaccine.2009.10.025

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposorne-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3748 / 3753

页数：6

共 50 条

[41] IMMUNOMODULATION OF EXPERIMENTAL MURINE HERPES-SIMPLEX KERATITIS .2. GLYCOPROTEIN-D PROTECTION
FOSTER, CS
SANDSTROM, IK
WELLS, PA
THOMPSON, P
DAIGLE, J
OPREMCAK, EM
[J]. CURRENT EYE RESEARCH, 1988, 7 (11) : 1051 - 1061
[42] Evaluation of a dominant-negative recombinant herpes simplex virus (HSV) type 1 as a vaccine against genital herpes in mice und guinea pigs
Brans, R.
[J]. HAUTARZT, 2010, 61 (12): : 1073 - 1077
[43] HERPES-SIMPLEX VIRUS GLYCOPROTEIN TREATMENT OF RECURRENT GENITAL HERPES REDUCES CERVICOVAGINAL VIRUS SHEDDING IN GUINEA-PIGS
MYERS, MG
BERNSTEIN, DI
HARRISON, CJ
STANBERRY, LR
[J]. ANTIVIRAL RESEARCH, 1988, 10 (1-3) : 83 - 88
[44] EFFICACY OF RECOMBINANT GLYCOPROTEIN-D SUBUNIT VACCINES ON THE DEVELOPMENT OF PRIMARY, RECURRENT, AND LATENT GENITAL INFECTIONS WITH HERPES-SIMPLEX VIRUS TYPE-2 IN GUINEA-PIGS
BERMAN, PW
VOGT, PE
GREGORY, T
LASKY, LA
KERN, ER
[J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (05): : 897 - 902
[45] Herpes simplex virus DNA vaccine efficacy: Effect of glycoprotein D plasmid constructs
Strasser, JE
Arnold, RL
Pachuk, C
Higgins, TJ
Bernstein, DI
[J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05): : 1304 - 1310
[46] Production and characterization of monoclonal antibody to glycoprotein D antigen of Herpes simplex virus type 2
Choi, YS
Kim, TU
Lee, HH
Cho, MH
[J]. JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2001, 11 (02) : 173 - 178
[47] PROTECTION FROM GENITAL HERPES-SIMPLEX VIRUS TYPE-2 INFECTION BY VACCINATION WITH CLONED TYPE-1 GLYCOPROTEIN-D
BERMAN, PW
GREGORY, T
CRASE, D
LASKY, LA
[J]. SCIENCE, 1985, 227 (4693) : 1490 - 1492
[48] PROTECTION OF GUINEA-PIGS AGAINST PRIMARY AND RECURRENT GENITAL HERPES INFECTIONS BY IMMUNIZATION WITH LIVE HETEROLOGOUS OR HOMOLOGOUS HERPES-SIMPLEX VIRUS - IMPLICATIONS FOR A HERPES-VIRUS VACCINE
SCRIBA, M
[J]. MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 1978, 166 (1-4) : 63 - 69
[49] GENITAL INFECTIONS DUE TO HERPES-SIMPLEX VIRUS TYPE-2 IN MALE GUINEA-PIGS
STEPHANOPOULOS, DE
MYERS, MG
BERNSTEIN, DI
[J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (01): : 89 - 95
[50] A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2
He, Zhuojing
Xu, Juan
Tao, Wei
Fu, Ting
He, Fang
Hu, Ruxi
Jia, Lan
Hong, Yan
[J]. MOLECULAR MEDICINE REPORTS, 2016, 14 (02) : 1823 - 1828

← 1 2 3 4 5 →